Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.

ABSTRACT:

Purpose

To report the clinical efficacy of sorafenib and to evaluate biomarkers associated with sorafenib clinical benefit in the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) program.

Patients and methods

Patients with previously treated non-small cell lung cancer (NSCLC) received sorafenib until progression or unacceptable toxicity. Eight-week disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were assessed. Prespecified biomarkers included K-RAS, EGFR, and B-RAF mutations, and EGFR gene copy number. Gene expression profiles from NSCLC cell lines and patient tumor biopsies with wild-type EGFR were used to develop a sorafenib sensitivity signature (SSS).

Results

A total of 105 patients wer

SUBMITTER: Blumenschein GR 

PROVIDER: S-EPMC3905243 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature